TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9081105

Group type: EXPERIMENTAL
Intervention: Heparin-coated cardiopulmonary bypass circuits (Duraflo II, n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard cardiopulmonary bypass circuits (n = 13)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Post-cardiopulmonary bypass
Number of subjects: 26
Study: 8228636

Group type: EXPERIMENTAL
Intervention: Sitostanol esters (3.4 g/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Rapeseed oil (control)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Sitostanol esters
Number of subjects: 67
Study: 3511706

Group type: EXPERIMENTAL
Intervention: Phenobarbital (500 mg intravenously)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 46
Study: 29741230

Group type: EXPERIMENTAL
Intervention: Internet-based self-management program (www.selfmanagescleroderma.com)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Patient-focused educational book
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Internet-based self-management program
Number of subjects: 267
Study: 29998337

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase at standard dose (0.9 mg/kg) with oral placebo (n=156)
Number of subjects: 948

Group type: COMPARATOR
Intervention: Oral aspirin, 325 mg, with intravenous placebo (n=157)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase
Number of subjects: 948

Group type: COMPARATOR
Intervention: Oral aspirin
Number of subjects: 948
Study: 27602507

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 408

Group type: COMPARATOR
Intervention: Medical care
Number of subjects: 408
Study: 25096595

Group type: EXPERIMENTAL
Intervention: Kirschner wire fixation
Number of subjects: 461

Group type: COMPARATOR
Intervention: Locking plate fixation
Number of subjects: 461
Study: 22730101

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) administered intravenously every 3-4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL)
Number of subjects: 0
Study: 20864814

Group type: EXPERIMENTAL
Intervention: JE/YF sequential vaccination
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: YF/JE sequential vaccination
Number of subjects: 108

Group type: COMPARATOR
Intervention: Co-administration of JE and YF
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: YF vaccine
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: JE vaccine
Number of subjects: 108
Study: 17013897

Group type: EXPERIMENTAL
Intervention: Active treatment (including 70 radical prostatectomy, 24 radiation, 10 endocrine treatment)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Active treatment (specifically radical prostatectomy)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Preoperative PSADT < 2 years
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Preoperative PSADT > 4 years
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Preoperative PSADT
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Surveillance
Number of subjects: 270
Study: 15334433

Group type: EXPERIMENTAL
Intervention: DHEA (200 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 11165427

Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Standard procedures of mediastinoscopy or thoracotomy
Number of subjects: 188
Study: 9545145

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiplatelet agents (aspirin and ticlopidine)
Number of subjects: 0
Study: 8138522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI) 2.5 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Imipramine (IMI)
Number of subjects: 18
Study: 2591079

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment under a hydrocolloid occlusive dressing
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4299208

Group type: EXPERIMENTAL
Intervention: Improved immunosuppression and better organ preservation in later cases (after July 1967)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Liver homografts with no specific intervention mentioned
Number of subjects: 17
Study: 30182376

Group type: EXPERIMENTAL
Intervention: Intervention group (health workers trained according to national guidelines)
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 617
Study: 28219619

Group type: EXPERIMENTAL
Intervention: HIV self-testing plus facility-based testing
Number of subjects: 362
Study: 26887211

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation of acupoints of the Conception Vessel, Kidney Meridian, Spleen Meridian, and Bladder Meridian
Number of subjects: 96

Group type: COMPARATOR
Intervention: Estradiol Valerate tablets and Estradiol Cyproterone
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Acupuncture group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 96
Study: 24205043

Group type: EXPERIMENTAL
Intervention: Supportive telephone counseling intervention (monthly sessions by practice nurses over 12 months)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Supportive telephone counseling intervention
Number of subjects: 204
Study: 22177466

Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting blood pressure control.
Number of subjects: 8690

Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting foot inspection.
Number of subjects: 8690

Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting glycaemic control.
Number of subjects: 8690

Group type: EXPERIMENTAL
Intervention: Educational messages attached to laboratory test reports targeting cholesterol control.
Number of subjects: 8690
Study: 19890181

Group type: EXPERIMENTAL
Intervention: Surgical treatment for symptomatic lumbar disc herniation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decompression for spinal stenosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decompression and fusion for degenerative spondylolisthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonsurgical care
Number of subjects: 0
Study: 16728212

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate lipid-lowering strategy
Number of subjects: 0
Study: 15199076

Group type: EXPERIMENTAL
Intervention: Daptomycin (6 mg/kg total body weight, administered intravenously over 30 minutes)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal volunteer control group (matched by weight, age, and sex)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Daptomycin in hepatic‐impaired patients
Number of subjects: 10
Study: 11704596

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 22
Study: 9393380

Group type: EXPERIMENTAL
Intervention: Immediate zidovudine therapy
Number of subjects: 204

Group type: COMPARATOR
Intervention: Deferred zidovudine therapy
Number of subjects: 204
Study: 8260299

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (including diazepam, morphine, and no premedication)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unpremedicated patients and those receiving diazepam
Number of subjects: 45
Study: 2888507

Group type: EXPERIMENTAL
Intervention: Ethanol (moderately intoxicating dose)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30741725

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation intervention in addition to a routine therapy program
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine therapy program
Number of subjects: 40
Study: 28863595

Group type: EXPERIMENTAL
Intervention: Randomized stimulation and averaging (RSA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Conventional averaging
Number of subjects: 3
Study: 25768238

Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline (30 mL/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preoperative oral acetazolamide (5 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22918839

Group type: EXPERIMENTAL
Intervention: Drug user stigma
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Larger size of drug network
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Current use of heroin, cocaine, and crack
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Homelessness in the past 6 months
Number of subjects: 340
Study: 21459216

Group type: EXPERIMENTAL
Intervention: Low-dose fluocinolone acetonide insert (0.2 μg/day)
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: High-dose fluocinolone acetonide insert (0.5 μg/day)
Number of subjects: 953

Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Both low- and high-dose inserts
Number of subjects: 953
Study: 19491822

Group type: EXPERIMENTAL
Intervention: Ketotifen 12 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ketotifen 4 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 16327334

Group type: EXPERIMENTAL
Intervention: Efavirenz 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Efavirenz 800 mg/day
Number of subjects: 0
Study: 12631604

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Control (no-TAM)
Number of subjects: 433
Study: 10692608

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 40
Study: 9355816

Group type: EXPERIMENTAL
Intervention: Individual treatment plus family treatment (education and training in communication and problem-solving skills)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Individual treatment
Number of subjects: 52
Study: 8454476

Group type: EXPERIMENTAL
Intervention: Medium dose rate brachytherapy (1000 cGy at 5 mm depth for three fractions)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy (1000 cGy at 10 mm depth for three fractions)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Low dose rate brachytherapy (750 cGy at 10 mm depth for three fractions)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Survival from diagnosis and first treatment for curative
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Survival from diagnosis and first treatment for palliative
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Survival from diagnosis and first treatment for recurrent
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 342
Study: 3778567

Group type: EXPERIMENTAL
Intervention: Tenoxicam with alcohol
Number of subjects: 12
Study: 30530580

Group type: EXPERIMENTAL
Intervention: Group-based chronic pain self-management course (2.5-hour weekly sessions for 6 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Low-impact outdoor group physical activity (1-hour weekly sessions for 6 weeks)
Number of subjects: 121
Study: 26818781

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 6202

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 6202

Group type: EXPERIMENTAL
Intervention: Dabigatran and Warfarin
Number of subjects: 6202
Study: 25225209

Group type: EXPERIMENTAL
Intervention: Copeptin levels in cases of preeclampsia
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Copeptin levels in cases diagnosed before 37 weeks
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Copeptin levels in cases diagnosed after 37 weeks
Number of subjects: 401

Group type: COMPARATOR
Intervention: Copeptin levels in controls
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Copeptin levels in gestational hypertension without proteinuria, gestational diabetes mellitus, or preterm birth
Number of subjects: 401
Study: 21830863

Group type: EXPERIMENTAL
Intervention: Memory questionnaires about a stressful event
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 263
Study: 20163785

Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (CT) for 8 months
Number of subjects: 84

Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 84
Study: 18855530

Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg/day
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (normotensives)
Number of subjects: 630
Study: 15738787

Group type: EXPERIMENTAL
Intervention: Advice to rest in bed
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advice to stay active
Number of subjects: 0
Study: 12180580

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: remifentanil 0.5 microg/kg and propofol 0.5 mg/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg with propofol 0.5 mg/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: saline 0.1 ml/kg
Number of subjects: 80
Study: 12196747

Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil
Number of subjects: 393

Group type: COMPARATOR
Intervention: 2% topical minoxidil
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 9640368

Group type: EXPERIMENTAL
Intervention: Nitrazepam (5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7864722

Group type: EXPERIMENTAL
Intervention: Lisinopril 2.5 to 5 mg/day
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Lisinopril 32.5 to 35 mg/day
Number of subjects: 3000
Study: 2532463

Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30467808

Group type: EXPERIMENTAL
Intervention: 300-mg bupivacaine (three INL-001 100-mg bupivacaine HCl collagen-matrix implants)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo collagen-matrix implants
Number of subjects: 417
Study: 28366698

Group type: EXPERIMENTAL
Intervention: Steroid avoidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 26165398

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg daily, increasing to a maximum of 2500 mg)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 22739125

Group type: EXPERIMENTAL
Intervention: Citalopram (CIT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acute Tryptophan Depletion (ATD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no pharmacological challenge)
Number of subjects: 20
Study: 21563888

Group type: EXPERIMENTAL
Intervention: Disruptive TMS over PMv during PP + AO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham TMS over frontal cortex during PP + AO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disruptive TMS over PMv during PP only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disruptive TMS over frontal cortex during PP only
Number of subjects: 0
Study: 18305997

Group type: EXPERIMENTAL
Intervention: Minimally invasive video-assisted thyroidectomy (MIVAT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 0
Study: 16874171

Group type: EXPERIMENTAL
Intervention: MenC‐TT vaccine coadministered with DTaP‐HBV‐IPV/Hib
Number of subjects: 230

Group type: COMPARATOR
Intervention: MenC‐CRM vaccine coadministered with DTaP‐HBV‐IPV/Hib
Number of subjects: 230
Study: 12629566

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (regular dietary advice, weight loss stimulation, increased physical activity)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (brief information about healthy diet and physical activity)
Number of subjects: 102
Study: 11110850

Group type: EXPERIMENTAL
Intervention: TOS (20 g/d)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference treatment (sucrose)
Number of subjects: 12
Study: 9168767

Group type: EXPERIMENTAL
Intervention: Cefoperazone alone
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Ceftriaxone with metronidazole
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Metronidazole, gentamicin, and ampicillin (triple-antibiotic group)
Number of subjects: 291
Study: 8467026

Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia with propofol/alfentanil combined with nitrous oxide
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 25
Study: 29799077

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 229

Group type: COMPARATOR
Intervention: No Digoxin
Number of subjects: 229
Study: 27182031

Group type: EXPERIMENTAL
Intervention: IDeg flexible dosing (±8 h from an agreed dosing time)
Number of subjects: 458

Group type: EXPERIMENTAL
Intervention: IDeg flexible dosing
Number of subjects: 458

Group type: COMPARATOR
Intervention: IDeg fixed dosing (at the same time each day)
Number of subjects: 458
Study: 24154700

Group type: EXPERIMENTAL
Intervention: palonosetron 0.075 mg i.v.
Number of subjects: 204

Group type: COMPARATOR
Intervention: placebo (normal saline i.v.)
Number of subjects: 204
Study: 22117892

Group type: EXPERIMENTAL
Intervention: Conventional treatment using removable partial dentures
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Functionally orientated treatment based on the shortened dental arch
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 44
Study: 20179007

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - loading dose of 140 mg/kg IV over 1 hour followed by 70 mg/kg IV every 4 hours for a total of 12 doses.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18568325

Group type: EXPERIMENTAL
Intervention: Volatile oil of amomum (VOA) 0.5 mL, thrice per day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Western tertiary medicinal treatment
Number of subjects: 80
Study: 15765452

Group type: EXPERIMENTAL
Intervention: Continuous interscalene block
Number of subjects: 30

Group type: COMPARATOR
Intervention: Continuous subacromial infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 12466507

Group type: EXPERIMENTAL
Intervention: Rhythm-control group (serial cardioversions, antiarrhythmic drugs, oral anticoagulants)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Rate-control group (oral anticoagulants, rate-slowing medication)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Rate-control group
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Rhythm-control group
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 522
Study: 10353071

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day
Number of subjects: 91

Group type: COMPARATOR
Intervention: Micronized fenofibrate 200 mg/day
Number of subjects: 91
Study: 7864418

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (0.75, 1.5, and 3 mg/70 kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fentanyl (0.1 mg/70 kg; positive control)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 1936479

Group type: EXPERIMENTAL
Intervention: Diet-Metformin combination
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 100
Study: 6179052

Group type: EXPERIMENTAL
Intervention: 500 mg sulfinpyrazone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31442695

Group type: EXPERIMENTAL
Intervention: Horror movie
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control movie
Number of subjects: 20
Study: 30120131

Group type: EXPERIMENTAL
Intervention: DAPP+ (dual antiplatelet therapy pretreatment)
Number of subjects: 790

Group type: COMPARATOR
Intervention: DAPP- (no dual antiplatelet therapy pretreatment)
Number of subjects: 790
Study: 27377542

Group type: EXPERIMENTAL
Intervention: Testosterone (7·5 g of 1% testosterone gel daily for 3 years)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo (gel)
Number of subjects: 308
Study: 25127170

Group type: EXPERIMENTAL
Intervention: Snack bars with 1.5 g β‐glucan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Snack bars with 3 g β‐glucan
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Snack bars with 6 g β‐glucan
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control bars (0 g β‐glucan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: White bread controls
Number of subjects: 12
Study: 22149921

Group type: EXPERIMENTAL
Intervention: ABVD alone
Number of subjects: 405

Group type: COMPARATOR
Intervention: Subtotal nodal radiation therapy
Number of subjects: 405
Study: 19234817

Group type: EXPERIMENTAL
Intervention: Intrathecal magnesium sulfate 50 mg (3 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Preservative-free 0.9% NaCl (3 ml)
Number of subjects: 60
Study: 17227906

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (20 mg/m2)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Liposomal daunorubicin (40 mg/m2)
Number of subjects: 79
Study: 15111532

Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg twice daily for 2 weeks)
Number of subjects: 30
Study: 11673300

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA) alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Preoperative Local Anesthesia (LA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Postoperative Local Anesthesia (LA)
Number of subjects: 90
Study: 9647457

Group type: COMPARATOR
Intervention: Epidural injection with 8 ml of saline (Group 1)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epidural block with 8 ml of 1% mepivacaine (Group 2)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Epidural block with a combination of 8 ml of 1% mepivacaine and 40 mg of methylprednisolone (Group 3)
Number of subjects: 53